Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection

被引:49
|
作者
Yönem, A
Çakir, B
Güler, S
Azal, Ö
Çorakçi, A
机构
[1] Gulhane Sch Med, Dept Endocrinol, Ankara, Turkey
[2] Ankara Educ & Res Hosp, Dept Endocrinol & Metab, Ankara, Turkey
来源
DIABETES OBESITY & METABOLISM | 2001年 / 3卷 / 05期
关键词
granulocyte-colony stimulating factor; diabetes mellitus; diabetic foot infection; respiratory burst; phagocytosis; polymorphonuclear leucocytes;
D O I
10.1046/j.1463-1326.2001.00142.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Foot infections and the subsequent amputation of a lower extremity are the most common cause of hospitalization among patients with diabetes mellitus. Although there are several reasons for susceptibility to infection in diabetic patients, white blood cell dysfunction is considered to be an important cause for this tendency. Granulocyte-colony stimulating factor (G-CSF) increases the release of neutrophils from the bone marrow and improves neutrophil functions. Based on this knowledge, the aim of the present study was to investigate the effects of addition of G-CSF to the treatment of foot infections in diabetic patients. Methods: Thirty diabetic patients with foot infection were included in the study. Fifteen of the patients received standard treatment consisting of local wound care and antibiotics (standard goup), and the other 15 patients received G-CSF besides standard treatment (G-CSF group). The objectives of this study were to determine the time to resolution of infection, time to hospital discharge, need for surgical intervention, and the effects of G-CSF on phagocytosis and respiratory burst of neutrophils. Results: Treatment with G-CSF led to significantly higher neutrophil counts on the 5th and loth days, and at the end of treatment in the G-CSF treated group compared to the standard group. Respiratory burst of neutrophils increased significantly in both the G-CSF group (from 1.6 +/-0.3 to 2.3 +/-0.5. p=0.001) and the standard group (from 2.0 +/-0.4 to 2.3 +/-0.4, p=0.02) with treatment. But, while phagocytosis of neutrophils increased significantly in the G-CSF group (from 70.4 +/-2.0 to 74.5 +/-1.9, p=0.004), it did not change significantly in the standard group (from 68.1 +/-0.2 to 69.4 +/-1.9, p=0.3) with treatment. Duration of hospitalization (26.9 +/-2.0 vs. 28.3 days, p<0.05), duration of parenteral antibiotic administration (22.9<plus/minus>2.0 vs. 23.3 +/-1.9 days, p<0.05), time to resolution of infection (23.6<plus/minus>1.8 vs. 22.3 +/-1.7 days, p<0.05), and need for amputation (13.3% vs. 20%, p>0.05) were similar between the G-CSF and the standard groups. Conclusions: Although G-CSF improves neutrophil function as well as increasing the absolute numbers, this improvement is not associated with shortening of duration of antibiotic administration, duration of hospital stay or need for amputation in diabetic foot infection.
引用
收藏
页码:332 / 337
页数:6
相关论文
共 50 条
  • [21] Granulocyte-Colony Stimulating Factor as Treatment Option in Patients with Recurrent Miscarriage
    Claudia Santjohanser
    Catherine Knieper
    Cordula Franz
    Kaino Hirv
    Osama Meri
    Manfred Schleyer
    Wolfgang Würfel
    Bettina Toth
    Archivum Immunologiae et Therapiae Experimentalis, 2013, 61 : 159 - 164
  • [22] Granulocyte-Colony Stimulating Factor as Treatment Option in Patients with Recurrent Miscarriage
    Santjohanser, Claudia
    Knieper, Catherine
    Franz, Cordula
    Hirv, Kaino
    Meri, Osama
    Schleyer, Manfred
    Wuerfel, Wolfgang
    Toth, Bettina
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2013, 61 (02) : 159 - 164
  • [23] Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy
    Locasciulli, A
    Arcese, W
    Locatelli, F
    Di Bona, E
    Bacigalupo, A
    LANCET, 2001, 357 (9249): : 43 - 44
  • [24] TREATMENT OF DRUG-INDUCED AGRANULOCYTOSIS WITH GRANULOCYTE-COLONY STIMULATING FACTOR
    MUROI, K
    ITO, M
    SASAKI, R
    SUDA, T
    SAKAMOTO, S
    MIURA, Y
    LANCET, 1989, 2 (8653): : 55 - 55
  • [25] Potential Application of Granulocyte-colony Stimulating Factor in the Treatment of Neurological Diseases
    Lee, Wang-Tso
    PEDIATRICS AND NEONATOLOGY, 2013, 54 (06): : 353 - 354
  • [26] Effects of recombinant granulocyte-colony stimulating factor administration during Mycobacterium avium infection in mice
    Gonçalves, AS
    Appelberg, R
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 124 (02): : 239 - 247
  • [27] Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients
    Ashrafi, Farzaneh
    Salmasi, Mehrzad
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2018, 23
  • [28] Aplastic anemia in pregnancy: treatment with cyclosporine and granulocyte-colony stimulating factor
    Ohba, T
    Yoshimura, T
    Araki, M
    Miyoshi, J
    Yonemura, Y
    Matsuura, K
    Okamura, H
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1999, 78 (05) : 458 - 459
  • [29] Effects of human granulocyte-colony stimulating factor on fracture healing in rats
    Bozlar, M
    Aslan, B
    Kalaci, A
    Baktiroglu, L
    Yanat, AN
    Tasci, A
    SAUDI MEDICAL JOURNAL, 2005, 26 (08) : 1250 - 1254
  • [30] Effects of Granulocyte-Colony Stimulating Factor After Stroke in Aged Rats
    Popa-Wagner, Aurel
    Stoecker, Kai
    Balseanu, Adrian Tudor
    Rogalewski, Andreas
    Diederich, Kai
    Minnerup, Jens
    Margaritescu, Claudiu
    Schaebitz, Wolf-Ruediger
    STROKE, 2010, 41 (05) : 1027 - 1031